Abstract:

Tuberculosis (TB) has afflicted humans for millennia and continues to pose a significant threat to public health worldwide. The World Health Organization classified TB as one of the top 10 causes of death globally, with approximately 10 million new cases and 1.4 million TB associated deaths in 2019 alone. Tuberculosis has high prevalence rates in certain regions, including Nigeria. Traditional diagnostic methods for TB and drug resistance diagnosis have limitations in accuracy and speed, highlighting the need for continuous studies on advanced molecular techniques. The study assessed the prevalence of tuberculosis and drug resistance among patients attending the National Tuberculosis and Leprosy Training Centre (NTBLTC), Saye Zaria using molecular techniques, with the aim of contributing to the improvement of diagnosis, treatment, and control strategies for tuberculosis. The cross-sectional study involved 342 suspected TB patients. Samples collected were analysed by microscopy, GeneXpert MTB/RIF and Line probe Assays. The results of this study showed an overall prevalence rate of 39.5% (p<0.05) of Mycobacterium Tuberculosis determined from GeneXPert MTB/RIF positive confirmed cases. further assay using Line Probe Assay (LPA) revealed an MDR-TB prevalence rate of 18(5.3%). Poly-resistance was also detected in 2 (0.58%). However, no Pre-Extensively Drug Resistant Tuberculosis (Pre-XDR-TB) and Extensively Drug Resistant-Tuberculosis (XDR-TB) were found. The overall results showed a slight but comparable rise in the prevalence of MTB against reviewed studies while the MDR-TB prevalence was lower. The study underscores the need for early diagnosis and treatment of TB to stall the occurrence of MDR-TB and other forms of severe TB infections.

References:

[1].   The World Health Organization (Global Tuberculosis Control: WHO Report 2010), Date of Access: 1/1/2011, https://www.who.int/publications/i/item/9789241564069.

[2].   Aliyu G., El-Kamary, S. S., Abimiku, A., Ezati, N., Mosunmola, I., Hungerford, L., Brown, C., Tracy, K. J., Obasanya, J., Blattner, W., 2013, Mycobacterial Etiology of Pulmonary Tuberculosis and Association with HIV Infection and Multidrug Resistance in Northern Nigeria. Tuberculosis Research Treatment, Doi: 10.1155/2013/650561.

[3].   Bassey, E. B., Momoh, M. A., Imadiyi, S. O., Udofia, E. B., Miri, F. S., Anukam, K. C., Epoke, J., Benka-Coker, M. O., Aluyi, H. S., 2005, The Trend of Pulmonary Tuberculosis in Patients Seen at DOTS Clinics in the Federal Capital Territory, Abuja, Nigeria. Public Health, 119(5):405-8. Doi: 10.1016/j.puhe.2004.05.012.

[4].   Iliyasu, Z, Babashani, M., 2009, Prevalence and Predictors of Tuberculosis Coinfection Among HIV-Seropositive Patients Attending the Aminu Kano Teaching Hospital, Northern Nigeria, J Epidemiol. 19(2):81-7. Doi: 10.2188/jea.je20080026.

[5].   World Health Organisation (Global Tuberculosis Control: A Short Update to the 2009 report), Date of Access:1/1/2009, https://www.who.int/publications/i/item/9789241598866.

[6].   World Health Organisation (Global Tuberculosis Report 2020), Date of Access: 15/10/2020, https://www.who.int/publications/i/item/9789240013131.

[7].   World Health Organisation, (Global Tuberculosis Report 2023), Date of Access: 7/11/2023, https://reliefweb.int/report/world/global-tuberculosis-report-2023

[8].   Mac-Fiberesima, G., Ayodele, M. B. O., and Aaron, U. U., Baseline Evaluation of the Shorter Regimen for Multidrug Resistant Tuberculosis in South-South, Nigeria. Sokoto Journal of Medical Laboratory Science, 4(3):54-61, https://www.researchgate.net/profile/Martins-Ayodele-2/publication/336775153.

[9].   Natasha N., and Manormoney P., 2017, Bacterial pili, with Emphasis on Mycobacterium Tuberculosis Curli Pili: Potential Biomarkers for Point – of care Tests And Therapeutics. Biomarkers; 22(2):93 – 105. DOI: 10.1080/1354750X.2016.1252960

[10].  World Health Organization, (Global Tuberculosis Report 2016). Date of Access: 7/11/2023, https://www.who.int/teams/global-tuberculosis-programme/tb-reports.

[11].  World Health Organization (Implementing Tuberculosis Diagnostics: A Policy Framework), Date of Access: 24/04/2015, https://www.who.int/publications/i/item/9789241508612.

[12].  Boehme, C. C., Nabeta, P, Hillemann, D., Nicol, M.P., Shenai, S., Krapp, F., Allen, J., Tahirli R., Blakemore, R., Rustomjee, R., Milovic, A., Jones M., O'Brien S. M., Persing, D. H., Ruesch-Gerdes, S., Gotuzzo, E., Rodrigues, C., Alland, D., Perkins, M. D.,2010, Rapid Molecular Detection of Tuberculosis and Rifampin Resistance. N Engl J Med., 363(11):1005-15. Doi: 10.1056/NEJMoa0907847.

[13].  Oladimeji, O., Atiba, B. P., Anyiam, F. E., Odugbemi, B. A., Afolaranmi, T., Zoakah, A. I., Horsburgh, C. R., 2023, Gender and Drug-Resistant Tuberculosis in Nigeria. Trop. Med. Infect. Dis., 8, 104. https://doi.org/10.3390/tropicalmed8020104.

[14].  Bai, Y., Wang, Y., Shao, C., Hao, Y., and Jin, Y., 2016, GenoType MTBDRplus assay for Rapid Detection of Multidrug Resistance in Mycobacterium Tuberculosis: A Meta-Analysis. PLoS ONE 11:e015032. Doi: 10.1371/journal.pone.0150321.

[15].  Javed, H., Bakuła, Z., Plen, M., ´Hashmi, H. J., Tahir, Z., Jamil, N., and Jagielski, T., 2018, Evaluation of Genotype MTBDRplus and MTBDRsl Assays for Rapid Detection of Drug Resistance in Extensively Drug-Resistant Mycobacterium Tuberculosis Isolates in Pakistan. Front. Microbiol. 9:2265. Doi: 10.3389/fmicb.2018.02265.

[16].  Hain Lifescience (GenoType MTBDRplus VER 2.0.) 2019, Identification of the M. Tuberculosis Complex and its Resistance to Rifampicin and/or Isoniazid from Pulmonary Clinical Specimens or Cultivated Samples. https://www.hain-lifescience.de/en/products/microbiology/mycobacteria/tuberculosis/genotype mtbdrplus.html.

[17].  Pius, O., John, A., Sunday, O., Mumini, A., 2020, Occurrence of Rifampicin Resistant and HIV Co-Infection Tuberculosis in Ikere-Ekiti, Nigeria. Mal J Med Health Sci 16(1): 168-172.

[18].  Onaiwu T. O., Judith O., Philomena E., Adeyemi T. K., Taofeek S. A., Isaac O. K., 2023, Gene Mutation Patterns of Mycobacterium Tuberculosis Complex and Associated Factors among Suspected Multidrug-Resistant Tuberculosis Patients in Osun State, South-West, Nigeria, Scientific African 22 (2023) e01968 https://doi.org/10.1016/j.sciaf.2023.e01968.

[19].  Lawson, L., Habib, A. G., Okobi, M. I., Idiong, D., Olajide, I., Emenyonu, N., Onuoha, N., Cuevas, L. E. & Ogiri, S. O., 2010, Pilot Study on Multidrug Resistant Tuberculosis in Nigeria, Annals of African Medicine, Vol. 9, No. 3, pp. 184-187.

[20].  Lawson, L., Yassin, M. A., Abdurrahman, S. T., Parry, C. M., Dacombe, R., Sogaolu, O. M., Ebisike, J. N., Uzoewulu, G. N., Lawson, L. O., Emenyonu, N., Ouoha, J. O., David, J. S., Davies, P. D. O. and Cuevas, L. E. 2011, Resistance to First-Line Tuberculosis Drugs in Three Cities of Nigeria. Tropical Medicine & International Health, 16: 974-980. https://doi.org/10.1111/j.1365-3156.2011.02792.x.

[21].  Daniel O., and Osman E., 2011, Prevalence and Risk Factors Associated with Drug Resistant TB in South West, Nigeria, Asian Pacific Journal of Tropical Medicine, Vol. 4, no. 2, pp. 148–151. Doi:10.1016/S1995-7645(11)60057-6.

[22].  Aminu, A. I. and Tukur, A. D., 2016, Detection of Multidrug Resistant Tuberculosis (mdr-tb) among Rifampicin-Resistant tb Patients Using Line Probe Assay (lpa) in Kano, Nigeria. Bayero Journal of Pure and Applied Sciences, 9(2): 1 – 8. http://dx.doi.org/10.4314/bajopas.v9i2.1.

[23].  Akwaowo, C. D, Ekpin, V ., Umoh, V., Jiman, O., Bassey, A., Antia, E., Usoroh, E., 2021, Prevalence and Outcomes of Multi Drug Resistant Tuberculosis in Akwa Ibom STATE NIGERIA: A Retrospective Study, World Journal of Applied Science and Technology, 13(1), 10 – 18. https://www.ajol.info/index.php/wojast/issue/view/20826.

[24].  Lin, Y. H., Tai , C. H., Li, C. R., Lin, C. F., Shi, Z. Y., 2012, Resistance Profiles and rpoB Gene Mutations of Mycobacterium Tuberculosis Isolates in Taiwan. J Microbiol Immunol Infect. 46(4):266-70. Doi: 10.1016/j.jmii.2012.06.008.

[25].  Rufai, S. B., Kumar, P., Singh, A., Prajapati, S., Balooni, V., Singh, S., 2014, Comparison of Xpert MTB/RIF with Line Probe Assay For Detection Of Rifampin-Monoresistant Mycobacterium Tuberculosis. J Clin Microbiol. 52(6):1846-52. Doi: 10.1128/JCM.03005-13.